MET and breast carcinoma: We found that bevacizumab increased the c-Met/β1 integrin complex formation in breast cancer cells, a potential mechanism of the preclinical observation that VEGF-targeted therapies (28) and bevacizumab (29) increase the metastatic potential of cancer cells.